Literature DB >> 17068003

Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France.

F Sahajian1, P Vanhems, F Bailly, J Fabry, C Trepo, M Sepetjan.   

Abstract

BACKGROUND: A screening campaign for hepatitis C virus (HCV) infection was carried out in eight health centres of Lyon from June 2003 until March 2004. The population targeted for screening was underprivileged individuals without any social insurance, protected by Couverture Mutuelle Universelle or Aide Médicale Etat (AME), to estimate the prevalence of anti-HCV antibodies in this population and to identify associated risk factors.
METHODS: After training in HCV infection and screening, 43 general practitioners participated in the campaign. Information about patient socio-demographics and risk factors was collected prior to proposing screening serology. Blood samples were often taken in health centres. Follow-up of positive cases was organised via the Reference Centre of HCV Infection in Lyon with possible specialised consultations in health centres.
RESULTS: The average age of the 988 individuals in the campaign was 37 years; 51% were women; 54% had a foreign nationality; 21% lived in sheltered accommodation; 19% were lodged in third-party accommodation; 9% were homeless; and 57% possessed less than euro562 (Revenu Minimum d'Insertion level). Screening was not proposed to nine patients because of medico-psychological problems. The acceptance rate for screening was 98.8% (967/979), and testing was carried out on 97.6% of these subjects (944/967). The prevalence of anti-HCV antibodies in the sample was 4.7% (44/944) (95% CI = 3.4-6.2). Nearly 80% of positive cases were unknown prior to the campaign. Multivariate logistic regression modelling identified lifetime injection drug use [odds ratios (OR) = 15.99; P < 0.0001], lifetime medical care in a foreign country (OR = 4.46; P = 0.001), and wearing tattoos (OR = 2.75; P = 0.048) as significant risk factors for carrying anti-HCV antibodies. Characteristics independently associated with HCV seropositivity were age between 40 and 49 years, AME benefits, and no social insurance.
CONCLUSION: Wide acceptance of screening, high prevalence of anti-HCV antibodies (much higher than in the French population in general), a high proportion of positive cases unknown beforehand, and satisfactory follow-up of seropositive patients are all factors which support the need for a screening campaign targeting HCV infection in underprivileged persons living in France.

Entities:  

Mesh:

Year:  2006        PMID: 17068003     DOI: 10.1093/eurpub/ckl233

Source DB:  PubMed          Journal:  Eur J Public Health        ISSN: 1101-1262            Impact factor:   3.367


  4 in total

1.  Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods.

Authors:  Angelique P A Vermeiren; Nicole H T M Dukers-Muijrers; Inge H M van Loo; Frans Stals; Dirk W van Dam; Ton Ambergen; Christian J P A Hoebe
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 2.  Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.

Authors:  Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

3.  Serological markers and risk factors associated with Hepatitis B virus infection among Federal Capital Territory prison inmates, Nigeria: Should we be concerned?

Authors:  Chioma Cindy Dan-Nwafor; Ikeola Adeoye; Kehinde Aderemi; Martins Onuoha; Elizabeth Adedire; Adebobola Bashorun; Damaris Osunkwo; Saheed Gidado; Muhammad Balogun; Suleiman Idris; Ibrahim Ade-Yusuf; Ekpedeme Udom; Patrick Nguku
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

4.  Meta-analysis: risk of hepatitis C virus infection associated with hospital-based invasive procedures.

Authors:  Paul Henriot; Mathieu Castry; Liem Binh Luong Nguyen; Yusuke Shimakawa; Kévin Jean; Laura Temime
Journal:  Aliment Pharmacol Ther       Date:  2022-06-27       Impact factor: 9.524

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.